Abpro and Celltrion Reveal Promising Preclinical Data for Bispecific T-Cell Engager ABP-102/CT-P72 Targeting HER2-Positive Cancers
27/4 20:10
Abpro and Celltrion announce a partnership to develop ABP-102/CT-P72, a promising therapy for HER2-positive cancers....